The body's innate ability to regenerate skin relies on cells located around hair follicles. When a wound is superficial, these cells can repair the damage. However, for deep wounds that go beneath the follicle level, this natural healing mechanism is lost, necessitating advanced treatments like Polarity Bio's SkinTE.
Diabetic patients often lose foot sensation, meaning they can develop serious wounds without knowing. Unlike a typical injury where pain forces a person to change behavior (e.g., limping), these patients continue applying pressure to the wound. This lack of a pain feedback loop prevents healing and often exacerbates the injury.
Unlike treatments that encourage skin to close from the periphery, Polarity Bio's SkinTE is applied directly into the wound bed. The patient’s own processed skin cells then engraft, gain a blood supply, and regenerate new, full-thickness skin throughout the entire area. This
SkinTE is a personalized therapy created from a patient's own skin sample. Despite the complexity of harvesting cells, processing them, and activating them into a healing state, Polarity Bio has streamlined logistics to deliver the final product back to the clinic for application in just four to ten days, which is critical for treating active wounds.
Moving from Phase 2 to Phase 3 trials, Polarity Bio didn't just increase patient numbers; it doubled the follow-up period from three to six months. This shift highlights a critical goal of late-stage trials: assessing the long-term durability of a treatment's effect—in this case, ensuring the healed wounds remain closed.